News

Mirapex (pramipexole) improved the quality of life for people with Parkinson’s disease compared to a placebo, according to a pooled analysis of several clinical trials. Quality of life improvements were seen regardless of disease stage, duration of treatment, or quality of life assessments before treatment. This analysis provided new…

In a webinar hosted by AC Immune, scientists discussed the various advantages of vaccines — ranging from their expected safety and long-lasting immune responses to potentially lower costs — in treating and possibly preventing Parkinson’s and Alzheimer’s disease. The “Key Opinion Leader” webinar, broadcasted on Aug.

Exercise can modify the connectivity of the brain’s pedunculopontine nucleus (PPN) with other areas of the brain in people with Parkinson’s disease and gait impairments, a study has found. Decreases in connectivity of the PPN on the left side of the brain after exercise were associated with motor improvements…

The University of Oxford Parkinson’s Disease Centre is working with Metabolon to identify metabolic biomarkers of Parkinson’s risk and progression that could lead to tailored disease treatments and better patient care. “Metabolon’s highly accurate data will enable the identification of metabolomic biomarkers crucial to understanding and better predicting…

Two nonprofits have joined in an international partnership to accelerate the development of therapies for Parkinson’s disease (PD), a neurodegenerative condition thought to affect 10 million people globally. The Parkinson’s Foundation will invest at least $3 million over the next three years in Parkinson’s Virtual Biotech, the treatment development arm…

The first patient has been dosed in a clinical trial testing Annovis Bio’s buntanetap as an oral therapy for early-stage Parkinson’s disease, the company announced. The Phase 3 clinical trial (NCT05357989) got started shortly after the U.S. Food and Drug Administration (FDA) gave the company the…

Enrollment is now complete for a Phase 2 trial of NYX-458, Aptinyx’s investigational therapy to treat cognitive impairment in people with Parkinson’s disease. After a pause in enrollment due to the COVID-19 pandemic, the trial resumed enrolling in April 2021. Now, a total of 99 adults, ages…

Seelos Therapeutics has been awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research to advance the development of its gene therapy candidate SLS-004 in people with Parkinson’s disease. SLS-004 aims to regulate the expression, or levels, of the SNCA gene, which provides instructions to produce…

The Massachusetts Institute of Technology (MIT) has developed a device that uses artificial intelligence (AI) to detect the presence and severity of Parkinson’s disease through patients’ breathing patterns. Because respiratory symptoms occur at early stages of the disease, researchers proposed that breathing assessment may help in diagnosing…

Patients with early-onset or familial forms of Parkinson’s disease (PD) had a higher burden of rare mutations in the PPARGC1A gene compared with healthy people, whereas no significant relationship was observed between these mutations and late-onset sporadic Parkinson’s, a study found. While the findings suggest that PPARGC1A could contribute to the…